Abstract
AbstractIn 2001, the German Multiple Sclerosis Society, facing lack of data, founded the German MS Registry (GMSR) as a long-term data repository for MS healthcare research. By the establishment of a network of participating neurological centres of different healthcare sectors across Germany, GMSR provides observational real-world data on long-term disease progression, sociodemographic factors, treatment and the healthcare status of people with MS. This paper aims to illustrate the framework of the GMSR. Structure, design and data quality processes as well as collaborations of the GMSR are presented. The registry’s dataset, status and results are discussed. As of 08 January 2021, 187 centres from different healthcare sectors participate in the GMSR. Following its infrastructure and dataset specification upgrades in 2014, more than 196,000 visits have been recorded relating to more than 33,000 persons with MS (PwMS). The GMSR enables monitoring of PwMS in Germany, supports scientific research projects, and collaborates with national and international MS data repositories and initiatives. With its recent pharmacovigilance extension, it aligns with EMA recommendations and helps to ensure early detection of therapy-related safety signals.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Flachenecker, P. & Stuke, K. National MS registries. J. Neurol. 255, 102–108 (2008).
2. Holstiege, J., Steffen, A., Goffrier, B. & Bätzing, J. Epidemiology of multiple sclerosis—A population-based, Germany-wide study. Versorgungsatlas 17(09), 1–16 (2017).
3. Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf (2015).
4. Flachenecker, P. et al. Multiple sclerosis registries in Europe—Results of a systematic survey. Mult. Scler. 20, 1523–1532 (2014).
5. Jalusic, K. O. et al. Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care. Mult. Scler. https://doi.org/10.1177/1352458520985118 (2021).
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献